Impact of Upcoming Daratumumab Subcutaneous Formulation for Treatment of Multiple Myeloma

Impact of Upcoming Daratumumab Subcutaneous Formulation for Treatment of Multiple Myeloma

Episodes

Specialty:

All

Year:

All

EP. 1: The Intravenous Administration of Monoclonal Antibodies

ByAjai Chari, MD,Daniel Verina, NP, Mount Sinai Health System

May 13th 2020

EP. 2: Intravenous Administration and Hepatitis

ByAjai Chari, MD,Daniel Verina, NP, Mount Sinai Health System

May 13th 2020

EP. 3: Medication Supplements Prior to IV Administration

ByAjai Chari, MD,Daniel Verina, NP, Mount Sinai Health System

May 13th 2020

EP. 4: Infusion-Related Adverse Events

ByAjai Chari, MD,Daniel Verina, NP, Mount Sinai Health System

May 13th 2020

EP. 5: Study Overview: COLUMBA and PLEIADES

ByAjai Chari, MD,Daniel Verina, NP, Mount Sinai Health System

May 13th 2020

EP. 6: Real-World Experience With SQ Monoclonal Antibodies

ByAjai Chari, MD,Daniel Verina, NP, Mount Sinai Health System

May 13th 2020

EP. 7: Community Advice: SQ Formulation of Daratumumab

ByAjai Chari, MD,Daniel Verina, NP, Mount Sinai Health System

May 13th 2020

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

The OncFive: Top Oncology Articles for the Week of 8/16

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC